Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled.
After baseline evaluation, the participants will be randomized to receive either Placebo or
Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.